Clinical Research Programs

 
News Articles for Clinical Research Programs top ^
BERKELEY, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) , a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call today, Monday, June 30, 2014, at 4:30 p.m. Eastern time to confirm the communication plan for its EYEGUARD™-B clinical program.
Sign-up for XOMA Call Today at 4:30pm ET/1:30pm PT to Confirm Communication Plan for EYEGUARD(TM)-B Clinical Program investment picks
Incyte Corporation (Nasdaq: INCY) today reported 2014 second-quarter financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company highlighted its strong financial position, driven by growing Jakafi sales in the U.S. and Jakavi ® (ruxolitinib) royalties outside the U.S., as well as the submission of the ruxolitinib supplemental New Drug Application (sNDA) in the U.S. for patients with uncontrolled polycythemia vera (PV). The Company also discussed its expanding clinical pipeline, which includes pivotal as well as proof of concept studies, and the multiple data presentations for the Company’s product candidates that were made at the recent American Society of Clinical Oncology (ASCO) meeting.
Sign-up for Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs investment picks
Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO , Sept.
Sign-up for Trovagene Expands Clinical Program with New Study Evaluating its Precision Cancer Monitoring Platform in Lung Cancer investment picks
Data from 25 accepted abstracts include results from: --
Sign-up for AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® investment picks
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014 BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation (NYSE:XON) to include chimeric antigen receptor T-cell (CAR-T) therapy.
Sign-up for ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update investment picks
Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO , July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June.
Sign-up for Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer investment picks
2014/8/5
-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- --
Sign-up for Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile investment picks
MORRIS PLAINS, N.J., Aug.
Sign-up for Immunomedics Announces Fiscal 2014 Results and Clinical Program Developments investment picks
Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept.
Sign-up for Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program investment picks
TORONTO , July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Sign-up for Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research Programs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Activities  |  Next: Clinical Research Study